- Forest Laboratories (FRX) is reportedly close to agreeing to buy Aptalis Holdings from private equity firm TPG Capital for $3B, with an announcement about the deal possible today.
- Forest has been looking to buy in treatments due to patent expirations on its own blockbuster drugs, such as the antidepressant Lexapro. Aptalis' therapies include those for cystic fibrosis and gastrointestinal disorders; the latter would complement Forest's Linzess.
- Aptalis filed for an IPO in late December in case TPG would be unable to sell the company.
Forest closes in on Aptalis for $3B
Jan 8 2014, 02:16 ET